# Cyclacel Pharmaceuticals, Inc. (BGMS)

**Exchange:** NASDAQ  
**Market cap:** $2M  
**Price:** $0.91 (+1.12%)

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $747,000 | $138,000 | -$8M | -$3M | $-6.45 |
| 2024 | $43,000 | — | -$12M | -$11M | $-501.60 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $8M | $1M | $7M | $4M | $2,000 |
| 2024 | $4M | $6M | -$2M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$14M | — | -$5M |
| 2024 | -$12M | — | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BGMS)